TITLE:
Primary Pulmonary Lymphoepithelioma-Like Carcinoma Demonstrates a Favorable Response to Tislelizumab Combined with Chemotherapy: A Case Report
AUTHORS:
Qianglong Lin, Xiaofen Ma
KEYWORDS:
Primary Pulmonary Lymphoepithelioma-Like Carcinoma, LELC, Tislelizumab, Immune Checkpoint Inhibitor
JOURNAL NAME:
Journal of Biosciences and Medicines,
Vol.13 No.2,
February
13,
2025
ABSTRACT: Background: Primary pulmonary lymphoepithelioma-like carcinoma (LELC) is a rare subtype of non-small cell lung cancer (NSCLC). Nevertheless, no universally acknowledged standards of care have been reported to be effective and productive for the treatment of this tumor. Materials and Methods: A patient with advanced primary pulmonary LELC was treated by employing a combination of tislelizumab and chemotherapy. Results: The patient displayed a favorable response to the combination therapy. The tumor size exhibited conspicuous abatement in contrast to the pre-treatment baseline, and the tumor markers normalized. Conclusion: The combination of immunotherapy with chemotherapy appears to be more effective than therapy alone for managing advanced primary pulmonary LELC. On that account, further clinical trials are imperative to establish this combination regimen as a potential first-line treatment option for advanced cases.